Anaptys Biosciences has raised $33.9 million in its second venture round. The San Diego-based biotech garnered money from Novo A/S, Frazier Healthcare Ventures, Alloy Ventures, and Avalon Ventures. Much of that money will be put to use advancing the company's technology for antibody development and optimization.
- check out the release for more
ALSO: Piedmont Pharmaceuticals has secured $8.5 million in Series B financing from CM Capital Investments of Brisbane, Australia, and other investors. Release
PLUS: Cambridge, MA-based Ensemble Discovery, a developer of a DNA-programmed chemistry platform for developing therapeutics and bioassays, has raised $15 million in Series B funding. Report